# Tri Harbor Holdings Corporation v. Sigmapharm Laboratories, LLC

> United States Bankruptcy Court, D. New Jersey · November 22, 2022

URL: https://www.frixlaw.com/law-library/cases/10459732

## Case

- **Court:** United States Bankruptcy Court, D. New Jersey
- **Decided:** November 22, 2022
- **Opinion:** 100trialcourt
- **Cited by:** 0 later opinions in the Frix Law Library

## Citator (automated)

- No negative treatment found by the automated citator. That is not the same as a confirmation that the case is good law; read the citing cases.
- Full citator and citing cases: https://www.frixlaw.com/law-library/cases/10459732

## Opinion text

NOVEMBER 22, 2022
United States Bankruptcy Court
Newark, NJ
By: Juan Filgueiras, Deputy

In Re Case No.: 19-13448 (VFP)
TRI HARBOR HOLDINGS CORPORATION, et al.,1

Chapter: 11
Debtor.

KAVOD PHARMACEUTICALS LLC (f/k/a RISING
Adv. Pro. No.: 19-2053 (VFP)
PHARMACEUTICALS, LLC, f/k/a RISING
PHARMACEUTICALS, INC.) and TRI HARBOR HOLDINGS
CORPORATION (f/k/a ACETO CORPORATION),

Plaintiffs,

v.
Judge Vincent F. Papalia
SIGMAPHARM LABORATORIES, LLC,
Defendant.

MEMORANDUM OPINION DENYING WITHOUT PREJUDICE SIGMAPHARM’S MOTION
IN LIMINE TO PRECLUDE USE OF PLAINTIFFS’ AUDIT PACKAGES AS EVIDENCE

LOWENSTEIN SANDLER LLP ELLIOTT GREENLEAF, P.C.
Attorneys for Plaintiffs, Kavod Pharmaceuticals LLC Attorneys for Defendant,
(f/k/a Rising Pharmaceuticals, LLC, f/k/a Rising Sigmapharm Laboratories, LLC
Pharmaceuticals, Inc.) and Tri Harbor Holdings Henry F. Siedzikowski, Esq.
Corporation (f/k/a Aceto Corporation) Andrew Estepani, Esq.
Reynold Lambert, Esq. Timothy Myers, Esq.
Wojciech F. Jung, Esq. Elliott Greenleaf, P.C.
Gavin J. Rooney, Esq. 925 Harvest Drive, Ste. 300
One Lowenstein Drive Blue Bell, PA 19422
Roseland, New Jersey 07068

1 The Liquidating Debtors in the chapter 11 cases and the last four digits of each Liquidating Debtor’s taxpayer
identification number are as follows: Tri Harbor Holdings Corporation (f/k/a Aceto Corporation) (0520); Tri Harbor
Chemical Holdings LLC (f/k/a Aceto Agricultural Chemicals LLC, f/k/a Aceto Agricultural Chemicals Corporation)
HONORABLE VINCENT F. PAPALIA
United States Bankruptcy Judge
I. INTRODUCTION
This matter comes before the Court on the motion (the “Motion”) filed by defendant
Sigmapharm Laboratories, LLC (“Sigmapharm”) to prevent Kavod Pharmaceuticals LLC, f/k/a
Rising Pharmaceuticals, LLC f/k/a Rising Pharmaceuticals, Inc. (“Rising”), and Tri Harbor
Holdings Corp., f/k/a Aceto Corporation (“Aceto”) (collectively, the “Plaintiffs”), which are two
of the nine jointly administered Debtor-entities, from admitting at trial certain “audit packages”
(described below), which Sigmapharm claims contain multiple layers of hearsay and are not
admissible under the business records exception at Fed. R. Evid. 803(6) or as a “summar[y] to

prove content” under Fed R. Evid. 1006. The Plaintiffs have filed an objection thereto, and
Sigmapharm, a reply. In their submissions, the parties incorporate by reference prior certifications
of corporate personnel and deposition excerpts. Sigmapharm, in particular, raises Plaintiffs’ prior
statements in which Plaintiffs, according to Sigmapharm, disavow that the Audit Packages are
business records under Fed. R. Evid. 803(6). Sigmapharm argues that the Audit Packages are
patently inadmissible as containing multiple layers of hearsay and are “litigation fueled”
documents that were modified by Plaintiffs’ expert. Plaintiffs dispute all these claims.
II. JURISDICTIONAL STATEMENT
The Court has jurisdiction over this matter under 28 U.S.C. § 1334(b) and the Standing
Orders of Reference entered by the United States District Court on July 10, 1984 and amended on

September 18, 2012. This is a core proceeding under 28 U.S.C. § 157(b)(2)(A), (B) [claims
allowance] and (O). In addition, a Bankruptcy Court has “jurisdiction to interpret and enforce its
own prior orders.” Travelers Indem. Co. v. Bailey, 557 U.S. 137, 151 (2009) (in that case, a
Confirmation Order entered ten (10) years earlier). Venue is proper in this Court under 28 U.S.C.
§ 1408. The court issues the following findings of fact and conclusions of law pursuant to Fed. R.
Bankr. P. 7052. To the extent that any of the findings of fact might constitute conclusions of law,
they are adopted as such. Conversely, to the extent that any conclusions of law constitute findings
of fact, they are adopted as such.
III. STATEMENT OF RELEVANT FACTS AND ARGUMENTS OF PARTIES

As the Court recognized in its October 27, 2022 Opinion Granting in Part and Denying in
Part Plaintiffs’ Motion to Limit or Bar Expert Testimony of Defendant’s Expert, Gregory Cowhey,
and as the parties seem to agree here, the two primary audit packages at issue on this Motion are
the one generated by Plaintiffs on January 21, 2019 for the arbitration that was compelled by the
District Court in Sigmapharm Labs., LLC v. Rising Pharmaceuticals, Inc., U.S. District Court,
Eastern District of Pennsylvania, Dkt. No. 2:18-cv-1238 (the “District Court Action”) and a second
audit package that was “updated” by Plaintiffs to, among other things, include additional
transactions over a longer time period and produced on May 15, 2020 in connection with the instant
adversary proceeding.2 At Exhibit 2 to its Motion, Sigmapharm has provided in electronic format

(and under seal) two Excel spreadsheets (with subparts) and an Excel cover sheet that indicate that
the “audit packages” relate to the May 15, 2020 submission and Audit Period II, previously
identified as running from April 1, 2016 through approximately April 19, 2019, the closing date
of Plaintiffs’ sale of assets to Shore Suven Pharma, Inc. (although the end date in several iterations
in the Excel spreadsheets is both earlier and later than April 19, 2019).3 In its brief, Sigmapharm
defines the “Audit Packages” as represented by these Excel spreadsheets:
Sigmapharm attaches the “Summary File” of each audit package iteration as Exhibit
2. Sigmapharm can provide each “audit package” in its entirety at the Court’s

2 Sigmapharm Br., at 25-26, Dkt. No. 117 (identifying first audit package of January 2019); Kavod Pharmaceuticals
LLC v. Sigmapharm Labs., LLC, 2022 WL 16543800, at *3 (Bankr. D.N.J. Oct. 27, 2022). The Court notes that, in
Sigmapharm’s companion motion to exclude certain documents created post-litigation, the specific documents subject
to Sigmapharm’s motion are not completely clear or defined.
request. The audit packages are large spreadsheets which cannot be readily attached
to this Motion. Sigmapharm will provide a copy of its Exhibit 2, and any other
spreadsheet exhibit in this Motion, to the Court via flash drive. Rising-Aceto also
revised its audit package via supplementary interrogatory response, which
Sigmapharm includes in its Exhibit 2.4

Sigmapharm also incorporates by reference Plaintiffs’ June 9, 2021 answer to Sigmapharm’s
interrogatory 3, which identifies as the “Audit Package” the “updated audit package Rising
provided to Sigmapharm in May 2020.”5
Sigmapharm raises five general arguments against the admission of the Audit Packages:
(i) the Audit Packages represent hearsay upon hearsay and were created largely after
the parties’ working relationship ended on March 23, 2018 and therefore were not
made nearly contemporaneously and in the ordinary course under Fed. R. Evid.
803(6)(A) through (C);

(ii) the Audit Packages were reviewed and revised by Alvarez & Marsal (“A&M”), the
financial firm of which Plaintiffs’ forensic expert, Ms. Laureen M. Ryan (“Ms.
Ryan”), is a Managing Director;

(iii) the Audit Packages include internally inconsistent information;

(iv) the Audit Packages include “information and theories that contradict the facts and
circumstances that existed” when Plaintiffs were in business;6 and

(v) the Audit Packages include inputs from unidentified sources and unidentified
operators; they are “litigation fueled” documents and not business records.7

Sigmapharm refers to the following, prior statements by Plaintiffs during this adversary
proceeding to undercut Plaintiffs’ present position that the Audit Packages are business records:
(i) November 9, 2021 Letter from Reynold Lambert, Esq., to the Court in response to
Sigmapharm’s objection to Plaintiffs’ request for the Court to appoint an
independent expert. Counsel states at footnote 3:

The initial audit package is not a profit sharing statement delivered in the
normal course of business; indeed, Rising transmitted that package close to one
year after Sigmapharm unlawfully terminated the Agreement. Instead, the

4 Sigmapharm Br., at 1 n.2, Dkt. No. 117. The Court has reviewed the Summary File and flash drive and finds that it
needs in person testimony to fully understand these documents and how and when they were created.
5 Sigmapharm Br., at 2, Pls.’ Answer to Interrogatory 3, Ex. 2 (electronic), Dkt. No. 117.
6 Sigmapharm Br., at 1-2, Dkt. No. 117.
initial audit package identified amounts owed as of a date certain, and provided
accruals for charges that were not yet processed;8

(ii) June 12, 2020 Letter from Reynold Lambert, Esq. to Timothy Myers, Esq. stating
that the May 15, 2020 Audit Package “is not subject to Rule 34.” Under the
provisions of Fed. R. Civ. P. 34(a)(1), Sigmapharm argues that this statement
necessarily means that the Audit Package does not represent “items in the
responding party’s possession, custody, or control”;9

(iii) A sequence of Exhibits (8 through 12) that purport to show that A&M worked on
the data that became the May 15, 2020 Audit Package and that Plaintiffs did not
disclose this fact until Sigmapharm pressed Plaintiffs on it;10

(iv) A sequence of accounting irregularities, including statement by A&M in a
document that Sigmpharm has called “A&M Audit Package Review Notes” that
questions Plaintiffs’ retention of $2.6 million in a damages calculation (A&M’s
interlineation declares: “A&M has not ‘blessed’ this inclusion”); and the failure to
reflect the partial sale of some $800,000 in inventory that was to have been
destroyed;11

(v) General and specific concerns about Plaintiffs’ accounting practices registered by
EisnerAmper; BDO; PricewaterhouseCoopers; Aceto’s internal auditors; and the
Securities and Exchange Commission (reports attached);12 and

(vi) December 18, 2020 deposition testimony of Eugene Hughes, Senior Vice President
of Finance for Rising Pharmaceuticals, Inc. from June 12, 2017 to April 19, 2019.13
Sigmapharm claims that Mr. Hughes’s testimony demonstrates that he did not
provide and did not know who provided the company data that went into the audit
samples based primarily on counsel’s direction not to answer based on attorney-
client privilege or work product grounds.14

8 Sigmapharm Br., at 5; Nov. 9, 2021 Letter, Ex. 3, Dkt. No. 117. Here, Plaintiffs’ Counsel appears to be referring to
the January 19, 2019 audit package sent to Sigmapharm in connection with this demand for an audit in the arbitration.
9 Sigmapharm Br., at 5; June 12, 2020 Email, Ex. 4, Dkt. No. 117.
10 Sigmapharm Br., at 8-9; Exs. 8-12, Dkt. No. 117. These include: Metadata disclosure for Audit Package(s); Ex, 8;
A&M Audit Package Review Notes, Ex. 9; June 10, 2020 Email from Timothy Myers, Esq. to Reynold Lambert, Esq.
demanding production of metadata, Ex. 10; July 29, 2020 Email response granting access to metadata, Ex. 11, Dec.
18, 2020 Hughes Dep. Tr. 237:3-239:1 (wherein Hughes testifies that an A&M accountant “performed a math check”
on an audit schedule), Ex. 12, Dkt. No. 117.
11 Sigmapharm Br., at 14-15; A&M Audit Package Review Notes, Ex. 9; Dec. 18, 2020 Hughes Dep. Tr. 241:18-
250:17, Ex. 12, Dkt. No. 117.
12 Sigmapharm Br., at 15-20; Exs. 26, 27, 28, 29, 30, 31, 32, Dkt. No. 117.
13 May 5, 2021 Decl. of Eugene Hughes ¶ 1, Dkt. No. 52 (for Mr. Hughes’s corporate status).
14 Sigmapharm Br., Dec. 18, 2020 Hughes Dep. Tr. 305:6-313:1, Ex. 12, Dkt. No. 117. Without assigning fault, the
Court finds that there are many attorney objections/interruptions in this testimony on privilege grounds with the result
that Mr. Hughes never appears to have a full chance to answer. Whether the Court would sustain the objections on
In its reply, Sigmapharm identifies two more Plaintiff statements that Sigmapharm deems
inconsistent with other statements by Plaintiffs about the character of the Audit Packages:
(i) Plaintiffs’ Counsel argues in the June 2, 2022 objection to Sigmapharm’s motion
under Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 592-93 (1993)
(to be heard with trial on the merits):

94. Sigmapharm’s assertion that Rising “admitted that the audit packages
are not business records” (SP Br. at 33) is nonsense. As the excerpted text
makes plain, counsel for Plaintiffs in a letter said that the “initial audit package
[was] not a profit sharing statement delivered in the normal course of
business,” which is true. Id. (emphasis added). Rising was required under the
Agreement to provide quarterly profit sharing statements to Sigmapharm
(Agreement § 8.3), and the audit package is not one of those statements. But
Rising can, of course, create more than one type of business record;15 and

(ii) Although Plaintiffs declare that the January 21, 2019 Audit Package (which
Sigmapharm says is not the subject of sampling) was produced before the Debtors
filed their bankruptcy petition (as evidence that it was not produced as a litigation
tool), Sigmapharm observes that Plaintiffs produced this January 21, 2019 package
in the District Court litigation to oppose Sigmapharm’s motion to compel an audit
in the arbitration.16

In its moving brief, Sigmapharm also complains generally about Plaintiffs’ litigation
strategy; these complaints do not appear to be directly relevant to the admissibility of the Audit
Packages. Sigmapharm complains that, while A&M worked to generate the May 15, 2020 Audit
Package, Plaintiffs’ expert, Ms. Ryan, on or about August 4, 2021, discovered a $1.9 million error
in Plaintiffs’ favor, but Plaintiffs’ Counsel did not disclose the error until February 28, 2022, when
Sigmapharm pressed him for it.17 Sigmapharm also argues that the December 18, 2020 deposition
testimony of Rising’s Eugene Hughes indicates that Plaintiffs increased their accounting for costs
of goods sold from their prelitigation practices to their post-litigation records by $1.17 million
(26.65%) to the detriment of each party’s profit share.18 Sigmapharm also draws in both the March

15 Sigmapharm Reply, at 5-6, Dkt. No. 129, quoting June 2, 2022 Pls.’ Obj. ¶ 94, Dkt. No. 103.
16 Sigmapharm Reply, at 8 n.2, Dkt. No. 129.
17 Sigmapharm Br., at 10-11, Dkt. No. 117.
11, 2022 deposition testimony of Ms. Ryan and the June 16, 2022 Affidavit of Gregory Cowhey,
Sigmapharm’s forensic expert (produced in response to Sigmapharm’s April 26, 2022 motion to
preclude reports and testimony of Plaintiffs’ Ms. Ryan, a motion to be addressed at trial) for the
propositions that Plaintiffs have not produced third-party documentary support for their accounting
entries (Mr. Cowhey) and that Ms. Ryan did not seek such documentary support or rely on it.19

Plaintiffs argue in their objection:
(i) that this Motion represents Sigmapharm’s third attempt (after Sigmapharm’s April
2, 2021 summary judgment motion (Dkt. No. 41) (decided by the October 5, 2021
Opinion) and Sigmapharm’s April 26, 2022 Daubert motion (Dkt.No. 98) (to be
decided at trial) to exclude the Audit Packages and that the October 5, 2021 Opinion
clearly deferred that decision to trial;20

(ii) that Eugene Hughes stated in his May 5, 2021 Declaration (filed in support of
Plaintiffs’ opposition to Sigmapharm’s motion for summary judgment) that he
knew how his team prepared the audit package and was responsible for preparing
the audit package for April 1, 2016 through December 31, 2018 (produced on
January 21, 2019), ultimately updated through April 30, 2020 (produced on May
15, 2020);21 and

(iii) that Sigmapharm agreed to the “sampling” procedure for testing the Audit Package
under a June 10, 2020 Rising Pharmaceuticals, Inc. Audit Testing Summary and
cannot renege on its agreement to accept that procedure and the Court indicated at
the April 22, 2021 hearing on multiple discovery requests that Sigmapharm’s
request for backup documentation as to all 400,000 transactions that Plaintiffs
assert occurred during the relevant time period was at that point “improper” as the
parties agreed to an audit protocol that was limited to approximately 400
transactions.22

19 Sigmapharm Br., at 22-24; June 16, 2022 Cowhey Aff., Ex. 33 (originally Ex. 31, Dkt. No. 105-1); Mar. 11, 2022
Ryan Dep. Tr. 67:9-21; 72:6-22; 78:1-79:18, Ex. 34, Dkt. No. 117.
20 Pls.’ Obj. ¶¶ 22-23, Dkt. No. 127; Kavod Pharmaceuticals, LLC v. Sigmapharm Labs., LLC, 2021 WL 4877265,
at *34 (Bankr. D.N.J. Oct. 5, 2021).
21 Sept. 9, 2022 Lambert Decl. ¶ 14, May 5, 2021 Hughes Decl. ¶ 52, Ex. A, Dkt. No. 127-1 (originally Dkt. No. 52).
22 Sept. 9, 2022 Lambert Decl., Rising Pharmaceuticals, Inc. Audit Testing Summary, Ex C, Dkt. No. 127-1. Plaintiffs
ascribe a June 10, 2020 date to this document, which is not dated. Plaintiffs also argue that Sigmapharm’s document
complaints came too late as they never moved to compel compliance with this Court’s June 7, 2021 Order or otherwise
seek additional documentation that Plaintiffs objected to. While the Court did rule that Plaintiffs were not required to
produce the backup for all 400,000 transactions, Plaintiffs were, however, required to produce the underlying
documentation related to the Audit Package sample or advise that they did not have those documents. Sigmapharm
argues that Plaintiffs did not comply with these requirements of the June 7th Order, which is an issue that also remains
Sigmapharm in its reply argues that Plaintiffs overstate the Court’s decision in the October
5, 2021 Opinion about when the Court would next consider Sigmapharm’s argument to exclude
the Audit Packages: the Court indicated on October 5, 2021 that such consideration “is more
appropriately left for a motion in limine or trial,” as the audit was then ongoing.23 Sigmapharm
also reiterates its primary arguments and charges Plaintiffs with having failed to address

Sigmapharm’s argument that the Audit Packages are inadmissible under Fed. R. Evid. 1006
(“Summaries to Prove Content”). That is not quite the case, although Plaintiffs hedge their
argument on this point, alleging: (i) that the Court may never need to determine whether the Audit
Packages are admissible summaries under Fed. R. Evid. 1006 because both the supporting data
and the spreadsheets are admissible business records under Fed. R. Evid. 803(6); and (ii) that, so
long as the underlying records qualify as business records under Fed. R. Evid. 803(6), it does not
matter if “the audit packages were prepared during litigation,” and that the master spreadsheet is
admissible as a summary under Fed. R. Evid. 1006.24
IV. LEGAL STANDARDS AND ANALYSIS

In the instant Motion, under the applicable Federal Rules of Evidence and relevant case
law cited below, the more the parties attempt to characterize the Audit Packages (whether as
business record, summary to prove content, or something else), the more obvious it becomes that
the Court can assess the merits of these arguments only at trial, after having reviewed the proffered
documents competently identified, the related testimony and the forensic reports of the parties’
representatives and experts tested against their trial testimony. While it is true that the Court
indicated that these types of issues may be raised in an in limine motion or at trial, based upon its
review of these underlying documents and these related in limine motions, the proper time to

23 Kavod, 2021 WL 4877265, at *34.
address these issues is at trial. This determination is consistent not only with the Court’s similar
ruling as to the post-litigation documents, but also with the Court’s prior rulings on Sigmapharm’s
summary judgment motion and Sigmapharm’s insistence that the Daubert motion to exclude Ms.
Ryan’s testimony be the subject of an evidentiary hearing, which the Court has determined will
occur at the same time as trial based on the overlapping issues involved in Sigmapharm’s Daubert

motion and one of the primary disputes that is to be resolved at trial, i.e., Plaintiffs’ compliance or
noncompliance with the Audit Provisions of the Agreement.
In sum, the complicated, overlapping and, in this Court’s view, inextricably intertwined
nature of the issues on these in limine motions and the issues that go to the heart of this case --
whether Plaintiffs breached the Audit Provisions of the Agreement -- require the Court to defer
this evidentiary issue to trial. This ruling is also consistent with the case law discussed
immediately below and the disputed factual record that is now before the Court.
A. The Business Records Exception to Hearsay under Fed. R. Evid. 803(6)
A motion in limine, filed before the trial:

requests that the Court “prohibit opposing counsel from referring to or offering
evidence on matters prejudicial to the moving party.” . . . The purpose of a motion
in limine is to bar “irrelevant, inadmissible, and prejudicial” issues from being
introduced at trial, thus “narrow[ing] the evidentiary issues for trial[.]” Evidence
should not be excluded pursuant to a motion in limine, unless it is clearly
inadmissible on all potential grounds. . . . The movant bears the burden of
demonstrating that the evidence is inadmissable on any relevant ground, and the
court may deny a motion in limine when it lacks the necessary specificity with
respect to the evidence to be excluded. . . . . Evidentiary rulings, especially ones
that encompass broad classes of evidence, should generally be deferred until trial
to allow for the resolution of questions of foundation, relevancy, and potential
prejudice in proper context.

Leonard v. Stemtech Health Sciences, Inc., 981 F. Supp. 2d 273, 276 (D. Del. 2013) (emphasis
supplied) (internal citations omitted). The Third Circuit in Bradley v. Pittsburgh Bd. of Ed., 913
F.2d 1064, 1069 (3d Cir. 1990) distinguished an in limine motion from a summary judgment
motion:
Unlike a summary judgment motion, which is designed to eliminate a trial in cases
where there are no genuine issues of fact, a motion in limine is designed to narrow
the evidentiary issues for trial and to eliminate unnecessary trial interruptions.

Bradley, 913 F.2d at 1069. In In re Depomed Pat. Litig., 2016 WL 743374, at *1-*2 (D.N.J. Feb.
22, 2016), the Court denied motions in limine to exclude evidence regarding the fundamentals of
the contested patent, as movant’s demands effectively asked the Court both to weigh evidence and
to draw conclusions of law (not merely to exclude evidence), and the Court could and should
address those demands at the bench trial, where “there is no risk of inadmissible evidence
improperly influencing a jury.” In re Depomed, 2016 WL 743374, at *2.
In the instant Motion, Sigmapharm seeks to preclude Plaintiffs from introducing at trial the
Audit Packages on the grounds that they are hearsay not subject to the business records exception
under Fed. R. Evid. 803(6) and they are not admissible under Fed. R. Evid. 1006 as “[s]ummaries
to prove content.” Before discussing these rules of evidence, the Court concurs with the general
rule cited above in the Depomed case that these complicated, mutually dependent and hotly
contested issues should be decided at trial.
The following summary of the relevant Federal Rules of Evidence leads to the business
records exception.
Fed. R. Evid. 402 (“General Admissibility of Relevant Evidence”) states in full:
Relevant evidence is admissible unless any of the following provides otherwise:

• the United States Constitution;
• a federal statute;
• these rules; or
• other rules prescribed by the Supreme Court.

Irrelevant evidence is not admissible.
Fed. R. Evid. 401 (“Test for Relevant Evidence”) also states in full:

Evidence is relevant if:

(a) it has any tendency to make a fact more or less probable than it would be without the
evidence; and

(b) the fact is of consequence in determining the action.

Fed. R. Evid. 403 (“Excluding Relevant Evident for Prejudice, Confusion, Waste of Time, or Other
Reasons”) authorizes the Court to exclude relevant evidence from consideration:
The court may exclude relevant evidence if its probative value is substantially
outweighed by a danger of one or more of the following: unfair prejudice, confusing
the issues, misleading the jury, undue delay, wasting time, or needlessly presenting
cumulative evidence.

Fed. R. Evid. 403. Plaintiffs have consistently argued throughout these in limine motions that Fed.
R. Evid. 403 “does not apply to bench trial because there are no concerns about unfairly prejudicing
a party.”25 As is noted in the Court’s opinion regarding Sigmapharm’s in limine motion as to post-
litigation documents at pp. 7-8, that is somewhat of an overstatement of the holdings of majority
of cases that Plaintiffs cite. Apex Fin. Options, LLC v. Gilbertson, 2022 WL 622130, at *1 (D.
Del. Mar. 3, 2022) (“Courts in this district have consistently exercised restraint in applying Rule
403 in a bench trial ‘because the Court is capable of assessing the probative value of the [evidence]
and excluding any arguably improper inferences’”) (emphasis supplied); UHS of Del., Inc. v.
United Health Servs., Inc., 2017 WL 1928340, at *1 (M.D. Pa. May 10, 2017) (“in the bench trial
context, Rule 403 is generally inapplicable, because a judge is unlikely to be misled or confused
by legal or factual nuance and is able to objectively assess probative value and reject any improper
inference”) (emphasis supplied); Suter v. General Acc. Ins. Co. of Am., 424 F. Supp. 2d 781, 790
(D.N.J. Mar. 30, 2006) (“in the context of a bench trial, evidence should not be excluded under
Rule 403 on the grounds that it is unfairly prejudicial, because the Court is capable of assessing
the probative value of the article and excluding any arguably improper inferences”) (internal
citations omitted).
Fed. R. Evid. 801 (“Definitions That Apply to This Article; Exclusions from Hearsay”)
defines hearsay at subsection (c)(1) and (2) as “a statement that: (1) the declarant does not make
while testifying at the current trial or hearing; and (2) a party offers in evidence to prove the truth

of the matter asserted in the statement.” Fed. R. Evid. 802 (“The Rule Against Hearsay”) provides
that hearsay is never admissible unless a federal statute; the Rules of Evidence; or other Supreme
Court Rules apply. Fed. R. Evid. 803 (“Exceptions to the Rule Against Hearsay—Regardless of
Whether the Declarant is Available as a Witness”) describes the “business records” exception to
hearsay at subsection 803(6):
The following are not excluded by the rule against hearsay, regardless of whether the
declarant is available as a witness:

(6) Records of a Regularly Conducted Activity. A record of an act, event,
condition, opinion, or diagnosis if:
(A) the record was made at or near the time by--or from information transmitted
by--someone with knowledge;

(B) the record was kept in the course of a regularly conducted activity of a
business, organization, occupation, or calling, whether or not for profit;

(C) making the record was a regular practice of that activity;

(D) all these conditions are shown by the testimony of the custodian or another
qualified witness, or by a certification that complies with Rule 902(11) or
(12)26 or with a statute permitting certification; and

(E) the opponent does not show that the source of information or the method or
circumstances of preparation indicate a lack of trustworthiness.

It is true that, as Sigmapharm argues, a document prepared for litigation may be deemed to
lack “trustworthiness” and “many of the normal checks upon . . . accuracy” that accompany a

26 Fed. R. Evid. 902 (“Evidence That Is Self-authenticating”) at (11) and (12) addresses “Certified Domestic [and
business record. Paddack v. Dave Christensen, Inc., 745 F.2d 1254, 1259 (9th Cir. 1984) (a special
audit report ordered by a trust fund trustee, who suspected irregularity, was not a business record
made in the ordinary course and was not admissible under the Fed. R. Evid. 803(6) exception to
hearsay); In re Hechinger Liquid. Trust, 298 B.R. 240, 242-43 (Bankr. D. Del. 2003) (a
“transaction detail report” generated by a third party for use by defendant in a bankruptcy

avoidance action was not protected by the Fed. R. Evid. 803(6) business records exception to
hearsay because there was no evidence that the report was made in the ordinary course of business
by the third-party creator). However, as was also noted in the Court’s Memorandum Opinion on
Sigmapharm’s Motion in limine regarding post-litigation documents, there is no blanket rule that
documents created after litigation begins are inadmissible. See Fed. Trade Comm’n v. Hackensack
Meridian Health, Inc., 2021 WL 4145062, at *23 (D.N.J. Aug. 4, 2021), aff’d, 30 F.4th 160 (3d
Cir. 2022) (a business record is not barred from admission simply because it was created after
litigation commenced, although the Court should decide what weight to give such a record); United
States v. Onyenso, 2013 WL 5322686, at *2 (D.N.J. Sept. 20, 2013) (“the mere existence of

pending litigation or an alternative motive does not require a blanket ban on legitimate business
records”).
In the instant Motion, there is nothing self-evident about the provenance and content of the
three large and multi-layered spreadsheets that Sigmapharm provided in electronic format at
Exhibit 2 and that themselves constitute only a “summary file” and not the complete Audit
Packages.27 The same is true of the underlying files that give rise to the “summary” and that were
provided to the Court by flash drive. Like the post-litigation documents, and Sigmapharm’s
overarching assertion that Plaintiffs failed to comply with the Audit Provisions of the Agreement
and, more specifically, failed to provide the underlying support for the Audit Packages and other
damages calculations, the Court will be able to assess the evidentiary competence and weight of
the Audit Packages only after they have been tested at trial through the forensic reports and
testimony of the parties’ representatives and experts and any other admissible evidence.28
B. Admissions of Summaries to Prove Content under Fed. R. Evid. 1006
Sigmapharm also argues that the Court should not admit the Audit Packages under Fed. R.

Evid. 1006 (“Summaries to Prove Content”), which allows the proponent of evidence to introduce
a summary of competent evidence in lieu of discrete and voluminous records under certain
conditions and states in full:
Fed. R. Evid. 1006 (“Summaries to Prove Content”)

The proponent may use a summary, chart, or calculation to prove the content of voluminous
writings, recordings, or photographs that cannot be conveniently examined in court. The
proponent must make the originals or duplicates available for examination or copying, or
both, by other parties at a reasonable time and place. And the court may order the proponent
to produce them in court.

Quoting 5 Weinstein’s Evidence ¶ 1006(02), p. 1006-6 (1983), the court in In re Summa T. Corp.,
Int’l, 73 B.R. 388, 392-93 (Bankr. E.D. Ark. 1987) explained: “Whether or not the originals are
introduced at the trial, the summaries may be relied upon as evidence-in-chief.” The Court in
United States v. Johnson, 594 F.2d 1253, 1255 (9th Cir.), cert. denied, 444 U.S. 964 (1979)
interpreted the Advisory Committee Note to the 1972 proposed rule as follows:
The purpose of Rule 1006 is to allow the use of summaries when the volume of
documents being summarized is so large as to make their use impractical or
impossible; summaries may also prove more meaningful to the judge and jury.

Johnson, 594 F.2d at 1255.

28 None of this detracts from the Court’s prior statement that Sigmapharm has provided substantial evidence in support
of its claim that Plaintiffs breached the Audit Provisions of the Agreement. Kavod, 2021 WL 4877265, at *30. Nor
does it detract from Plaintiffs’ ability to seek to show otherwise. Of course, the final determination of this vigorously
disputed issue must await trial because of the many overlapping disputed issues of fact involved in deciding whether
Here, Sigmapharm relies on a series of cases such as County of Wash. v. U.S. Bank, N.A.,
2012 WL 3860474, at *14, *15, *22, *24-*25, *27 (W.D. Pa. Aug. 17, 2012), R. & R. adopted,
2012 WL 3860438 (W.D. Pa. Sept. 5, 2012). In that case, at an evidentiary hearing incident to
defendant’s motion to remand, the Court refused to admit a summary of 715 mortgage transactions,
where the proponent could not produce the underlying documentation; the proffered compilation

appeared to be a “summary of summaries”; and the vice president called upon to testify about the
accuracy of the summary could state only that the data were gleaned from various sources not kept
in the ordinary course of business and that she had no knowledge of the underlying records, with
the result that the court deemed the summary mere hearsay. The Court thus remanded the matter,
as defendant failed to prove that the amount in controversy met the jurisdictional threshold. County
of Wash., 2012 WL 3860474, at *27.
Similarly, as Sigmapharm argues, summaries that include interpretations, argument or
conclusions are not admissible under Fed. R. Evid. 1006. Universal Furniture Int’l, Inc. v.
Collezione Europa USA, Inc., 599 F. Supp. 2d, 648, 650, 654, 656 (M.D.N.C. 2009) (in an opinion

after a bifurcated evidentiary hearing on damages, excluding a summary that included a cost
calculation that differed from the witness’s testimony about how costs should be calculated, as the
discrepancy created the false impression that a foundation had been laid for the anomalous
calculation in the summary); Allison v. Dolich, 2018 WL 834919, at *11 (D. Ore. Feb. 12, 2018)
(on plaintiff-employees’ motion for summary judgment, excluding as an exhibit a summary of
payroll records that contained plaintiffs’ preferred calculation of damages that exceeded the data
found in the underlying records, even though the underlying records were admissible under Fed.
R. Evid. 803(6)); First Fin. Bank, N.A. v. Bauknecht, 71 F. Supp. 3d 819, 835-36 (C.D. Ill. 2014)
(on plaintiffs’ motion for summary judgment, excluding as an exhibit a summary that contained
implicit argument that losses included on a spreadsheet resulted from alleged breach of contract
by defendant former employee); In re King, 2020 WL 6066015, at *2 (Bankr. N.D. Ga. Oct. 14,
2020) (“[e]ven if the underlying documents are admissible,” the summary is not if it “attempts to
present conclusions about the underlying documents”) (on plaintiff’s side-objection to defendant’s
opposition to plaintiff’s motion for summary judgment, excluding a spreadsheet summary in which
a party-in-interest without forensic training purported to “track” an adversary’s deposits and

expenditures).
Not surprisingly, Plaintiffs cite a string of cases that generally resulted in different rulings.
In Musket Corp. v. Star Fuel of Okla., LLC, 2012 WL 4758082, at *4 (W.D. Okla. Oct. 5, 2012),
the adversary argued that the court should exclude the proponent’s Excel spreadsheets because the
proponent had not provided underlying documents. On a Daubert motion without an evidentiary
hearing, the proponent persuaded the court that proponent used the spreadsheets in the ordinary
course of business, and the court admitted them under Fed. R. Evid. 803(6). Musket Corp., 2012
WL 4758082, at *4. In Habersham Plantation Corp. v. Molyneux, 2011 WL 13216995, at *9-*10
(S.D. Fla. Dec. 5, 2011), the court denied adversary’s motion in limine (without an evidentiary

hearing) to exclude proponent’s sales spreadsheets under Fed. R. Evid. 1006 on the grounds that
proponent had not supported them with underlying records; the proponent persuaded the court that
these spreadsheets were the raw data and that proponent used no other business records). Plaintiffs
also rely on United States v. Clotaire, 963 F.3d 1288, 1294 (11th Cir. 2020), cert. denied, 141 S.
Ct. 1743 (2021) (not a Rule 1006 case), a criminal matter which appears to involve somewhat
different circumstances, but did allow a “summary” that was based on some data that was not
utilized by the proponent in the ordinary course. In this decision, which followed the appeal of
several evidentiary rulings after trial, the court decided that a mere “format change” in the
proffered evidence with no change in their “communicative content” (substituting still photographs
for a surveillance video in a case involving identity theft of employment benefits; printing out an
electronically stored government data set onto a spreadsheet for admission at trial, even though the
litigant did not use printed spreadsheets in the ordinary course of business) did not prevent
admission of these elements of evidence as a business record. Clotaire, 963 F.3d at 1292, 1293-
94.
As the description of these cases indicates, some were decided after an evidentiary hearing

or trial, while others were decided on motion without an evidentiary hearing. In this case, the
Court’s ability to assess on a motion in limine whether the Audit Packages are admissible under
Fed. R. Evid. 1006 as a “summary to prove content” is even more difficult and remote than is its
ability to assess their admissibility under Fed. R. Evid. 803(6), as the former is dependent on the
latter (and the Plaintiffs’ argument that the Audit Packages themselves are business records). In
this Court’s view, the reliability of the underlying source data; the relationship between the Audit
Packages and the underlying data; the exploration of whether the Audit Packages contain
interpretations, argument or conclusions that would disqualify them for admission under Fed. R.
Evid. 1006; and Plaintiffs’ return to the argument that the Audit Packages in summary and “raw”

form are business records under Fed. R. Evid. 803(6), all require further testimony and other
evidence to establish. For the reasons previously stated, including the Court’s prior rulings that
expressed a likelihood that these types of issues would have to be decided at trial, the vigorously
and directly disputed nature of the submissions as to substance and admissibility, the highly
technical nature of the submissions and their direct relationship to the issues at the heart of this
case, the Court confirms that these issues will also be decided at trial.
V. CONCLUSION
For the reasons set forth above, Sigmpharm’s Motion in limine to exclude the Audit
Packages as evidence under Fed. R. Evid. 803(6) or Fed. R. Evid. 1006 is DENIED, without
prejudice to Sigmapharm’s right to seek to exclude the Audit Packages during trial.
A conforming Order is being entered contemporaneously with this Opinion.

Date: November 22, 2022 Vincent F. bey alee
VINCENT F. PAPALIA
United States Bankruptcy Judge

18

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/cases/10459732. Public record. Not legal advice.